Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.
IPO Year: 2021
Exchange: NASDAQ
Website: ternspharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2025 | $20.00 | Neutral → Buy | H.C. Wainwright |
| 11/3/2025 | Mkt Perform → Outperform | William Blair | |
| 10/15/2025 | $20.00 | Buy | Truist |
| 9/17/2025 | $15.00 | Overweight | Barclays |
| 9/4/2025 | Neutral | H.C. Wainwright | |
| 2/28/2025 | Mkt Perform | William Blair | |
| 10/31/2024 | $82.00 | Outperform | Oppenheimer |
| 6/22/2023 | $16.00 | Buy | Mizuho |
| 6/7/2023 | $18.00 | Buy | Jefferies |
| 5/31/2023 | $23.00 | Buy | ROTH MKM |
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
424B5 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
424B5 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
S-3ASR - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
10-Q - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
SCHEDULE 13D/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
144 - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
Fastest customizable press release news feed in the world
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are $747.5 million. All of the securities were off
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an add
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares and pre-funded warrants to be sold in th
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m. GMT. A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns' website for at least 30 days following the event. About Terns PharmaceuticalsTerns Pharmaceuticals is a clinical-stage oncology company reimagining known biology
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted options to purchase 252,500 shares, in the aggregate, of Terns common stock to the new employees
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hema
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leukemia with clinical data this quarter FOSTER CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of sm
FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00
William Blair upgraded Terns Pharmaceuticals from Mkt Perform to Outperform
Truist initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Barclays initiated coverage of Terns Pharmaceuticals with a rating of Overweight and set a new price target of $15.00
H.C. Wainwright resumed coverage of Terns Pharmaceuticals with a rating of Neutral
William Blair initiated coverage of Terns Pharmaceuticals with a rating of Mkt Perform
Oppenheimer initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $82.00
Mizuho initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $16.00
Jefferies initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $18.00
ROTH MKM initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $23.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
Live Leadership Updates
FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor
FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide
Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) expected in December 2024 Cash, cash equivalents and marketable securities of $225 million, expected to provide runway into 2026 FOSTER CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial res
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through transformational growth and transactions. "Elona's proven leadership and deep industry knowledge make her an ideal addition to the Terns team," said Amy Burroughs, chief executive officer of
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in 2H24 Cash, cash equivalents and marketable securities of $241 million, expected to provide runway into 2026 FOSTER CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2024 and pr
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Scott Harris as chief development officer (CDO) effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be transitioning her responsibilities and leaving the company to pursue other opportunities effective June 3, 2024. Mr. Harris will report to the CEO and oversee clinical operations, regulato
Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in second half of 2024 Cash, cash equivalents and marketable securities of $263 million, expected to provide runway into 2026 FOSTER CITY, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported
FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023. Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving
FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company's Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Corporation plc and brings to the Terns Board of Directors more than 15 years of experience in drug development. "Terns' approach of discovering and developing next-generation small molecules for clini
This live feed shows all institutional transactions in real time.
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13D/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13D/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
Live finance-specific insights
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hema
Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from
TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction of 45% as assessed by MRI-PDFF with 64% of patients achieving >30% PDFF reduction All TERN-501 doses were well-tolerated with no gastrointestinal and no cardiovascular safety signals Company to host conference call and webcast at 4:30 pm ET today FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidate